Affymetrix Inc. (AFFX) Receives FDA Clearance for Gene Expression Technology

QualityStocks would like to highlight Affymetrix (NASDAQ: AFFX). The company’s technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes.

In the company’s news yesterday,

Affymetrix announced it has received U.S. Food and Drug Administration clearance for the addition of new gene expression reagents as accessories to the company’s GeneChip® Microarray Instrument System for in vitro diagnostic (IVD) use, positioning Affymetrix as the first company in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives.

The Affymetrix gene expression platform is a comprehensive system used for enabling the development of clinical diagnostic tests. The company said the technology was designed to reduce development time by easing the regulatory burden and delivering reproducible results.

“Affymetrix created the technology and marketplace for multiplexed gene expression more than a decade ago, and this clearance of our gene profiling reagent kit by the FDA marks another milestone in our leadership in this important market segment,” Kevin King, president and CEO of Affymetrix stated in the press release.

King noted that Affymetrix’s products are used by thousands of research customers and powered by Affymetrix™ (PbA) partners, which use its research products on a daily basis to identify signatures or expression patterns that may lead to a cancer diagnostic or an improved therapy determination for patients.

“These customers can now seamlessly migrate from basic signature discovery to validation on a robust system,” he said.

The company also highlighted its operations and its position in the healthcare industry.

“Customers who are commercializing products on the Affymetrix clinical platform can rely on our proven technology, global distribution, services, and support organization,” said Affymetrix chief commercial officer Andy Last. “Affymetrix is leading the industry into the era of personalized medicine by turning our knowledge about biology, genes, and disease into tangible clinical applications, and ultimately, into diagnostic decisions that improve quality of life.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.